Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 10, 2009, Pages 1055-1068

  Murugesan, S V M ^a   Varro, A ^a   Pritchard, D M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; GLUCAGON; GLUCONATE CALCIUM; HISTAMINE H2 RECEPTOR ANTAGONIST; PENTAGASTRIN; PENTETREOTIDE IN 111; PROTON PUMP INHIBITOR; SECRETIN;

ACHLORHYDRIA; ANGIOGRAPHY; ATROPHIC GASTRITIS; CHRONIC KIDNEY FAILURE; CROHN DISEASE; DISEASE ASSOCIATION; GASTRECTOMY BILLROTH II; GASTRIN BLOOD LEVEL; GASTRINOMA; HELICOBACTER INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGASTRINEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; PYLORUS STENOSIS; REVIEW; SECRETIN BLOOD LEVEL; SIDE EFFECT; STOMACH PH; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VAGOTOMY; ZOLLINGER ELLISON SYNDROME;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; GASTRINOMA; GASTRINS; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; SECRETIN; ZOLLINGER-ELLISON SYNDROME;

EID: 64849096677     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03976.x     Document Type: Review

References (106)

1. Peach HG, Barnett NE. Determinants of basal plasma gastrin levels in the general population. J Gastroenterol Hepatol 2000 15 : 1267 71.
2. Jassel SV, Ardill JE, Fillmore D, Bamford KB, O'Connor FA, Buchanan KD. The rise in circulating gastrin with age is due to increases in gastric autoimmunity and Helicobacter pylori infection. QJM 1999 92 : 373 7.
3. Frucht H, Howard JM, Slaff JI, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989 111 : 713 22.
4. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006 85 : 295 330.
5. Campana D, Piscitelli L, Mazzotta E, et al. Zollinger-Ellison syndrome. Diagnosis and therapy. Minerva Med 2005 96 : 187 206.
6. Roy PK, Venzon DJ, Feigenbaum KM, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001 80 : 189 222.
7. Berger AC, Gibril F, Venzon DJ, et al. Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome. J Clin Oncol 2001 19 : 3051 7.
8. Kirton CM, Wang T, Dockray GJ. Regulation of parietal cell migration by gastrin in the mouse. Am J Physiol Gastrointest Liver Physiol 2002 283 : G787 93.
9. Chen D, Zhao CM, Dockray GJ, et al. Glycine-extended gastrin synergizes with gastrin 17 to stimulate acid secretion in gastrin-deficient mice. Gastroenterology 2000 119 : 756 65.
10. Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2007 23 : 595 601.
11. Dockray GJ. Clinical endocrinology and metabolism. Gastrin. Best Pract Res Clin Endocrinol Metab 2004 18 : 555 68.
12. Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 2001 63 : 119 39.
13. Johnson LR, Grossman MI. Characteristics of inhibition of gastric secretion by secretin. Am J Physiol 1969 217 : 1401 4.
14. Miyazaki Y, Shinomura Y, Tsutsui S, et al. Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology 1999 116 : 78 89.
15. Varro A, Ardill JE. Gastrin: an analytical review. Ann Clin Biochem 2003 40 : 472 80.
16. Rehfeld JF. The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand J Clin Lab Invest 2007 : 1 9.
17. Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007 52 : 2482 9.
18. Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001 13 : 1449 56.
19. Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006 24 : 1305 20.
20. Korman MG, John DJ, Hansky J. Studies on serum gastrin levels in pernicious anaemia. Gut 1970 11 : 981.
21. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 1955. CA Cancer J Clin 1989 39 : 231 47.
22. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954 16 : 363 71.
23. Lamers CB, Stadil F, Van Tongeren JH. Prevalence of endocrine abnormalities in patients with the Zollinger-Ellison syndrome and in their families. Am J Med 1978 64 : 607 12.
24. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 1998 5 : 77 85.
25. Regan PT, Malagelada JR. A reappraisal of clinical, roentgenographic, and endoscopic features of the Zollinger-Ellison syndrome. Mayo Clin Proc 1978 53 : 19 23.
26. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000 79 : 379 411.
27. Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996 89 : 653 69.
28. Skogseid B, Eriksson B, Lundqvist G, et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991 73 : 281 7.
29. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987 317 : 1200 9.
30. Zollinger RM, Ellison EC, O'Dorisio TM, Sparks J. Thirty years' experience with gastrinoma. World J Surg 1984 8 : 427 35.
31. Kaplan EL, Horvath K, Udekwu A, et al. Gastrinomas: a 42-year experience. World J Surg 1990 14 : 365 75.
32. Pipeleers-Marichal M, Donow C, Heitz PU, Kloppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 1993 17 : 481 8.
33. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004 83 : 43 83.
34. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005 242 : 64 73.
35. Trudeau WL, McGuigan JE. Serum gastrin levels in patients with peptic ulcer disease. Gastroenterology 1970 59 : 6 12.
36. Webster MW, Barnes EL, Stremple JF. Serum gastrin levels in the differential diagnosis of recurrent peptic ulceration due to retained gastric antrum. Am J Surg 1978 135 : 248 52.
37. Friesen SR, Tomita T. Pseudo-Zollinger-Ellison syndrome: hypergastrinemia, hyperchlorhydria without tumor. Ann Surg 1981 194 : 481 93.
38. Korman MG, Scott DF, Hansky J, Wilson H. Hypergastrinaemia due to an excluded gastric antrum: a proposed method for differentiation from the Zollinger ellison syndrome. Aust NZJ Med 1972 2 : 266 71.
39. Hallgren R, Karlsson FA, Lundqvist G. Serum level of immunoreactive gastrin: influence of kidney function. Gut 1978 19 : 207 13.
40. Watanabe H, Hiraishi H, Ishida M, Kazama JJ, Terano A. Pathophysiology of gastric acid secretion in patients with chronic renal failure: influence of Helicobacter pylori infection. J Intern Med 2003 254 : 439 46.
41. Korman MG, Laver MC, Hansky J. Hypergastrinaemia in chronic renal failure. Br Med J 1972 1 : 209 10.
42. Borazan A, Cavdar Z, Saglam F. The effect of renal replacement therapies on serum gastrointestinal system hormones. Ren Fail 2007 29 : 1019 23.
43. Feurle G, Ketterer H, Becker HD, Creutzfeldt W. Circadian serum gastrin concentrations in control persons and in patients with ulcer disease. Scand J Gastroenterol 1972 7 : 177 83.
44. Tani M, Shimazu H. Meat-stimulated gastrin release and acid secretion in patients with pyloric stenosis. Gastroenterology 1977 73 : 207 10.
45. Triantafillidis JK, Tzourmakliotis D, Peros G, et al. Serum gastrin levels in patients with inflammatory bowel disease. Hepatogastroenterology 2003 50 Suppl 2 : cccxv cccxvii.
46. Fabris P, Pilotto A, Bozzola L, et al. Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4 + cell count and Helicobacter pylori infection. Aliment Pharmacol Ther 2002 16 : 807 11.
47. Corleto VD, Minisola S, Moretti A, et al. Prevalence and causes of hypergastrinemia in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 1999 84 : 4554 8.
48. Romeo DP, Weesner RE, Giannella RA. Misdiagnosis of the Zollinger-Ellison syndrome due to hyperlipidemia. Gastroenterology 1990 99 : 1511 3.
49. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006 98 : 4 19.
50. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001 15 : 1795 806.
51. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993 104 : 1356 70.
52. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001 64 : 205 13.
53. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 1990 4 : 131 8.
54. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008 53 : 385 93.
55. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001 33 : 32 5.
56. Festen HP, Thijs JC, Lamers CB, et al. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology 1984 87 : 1030 4.
57. Maton PN. Review article: the management of Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993 7 : 467 75.
58. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004 25 : 458 511.
59. Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006 84 : 173 82.
60. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001 15 : 87 103.
61. Calam J. Helicobacter pylori. Eur J Clin Invest 1994 24 : 501 10.
62. Dockray GJ. Gastrin, growth, and colon neoplasia. Gut 2000 47 : 747 8.
63. Wagner S, Haruma K, Gladziwa U, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994 89 : 1211 8.
64. Tham TC, Chen L, Dennison N, et al. Effect of Helicobacter pylori eradication on antral somatostatin cell density in humans. Eur J Gastroenterol Hepatol 1998 10 : 289 91.
65. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992 340 : 930 2.
66. Queiroz DM, Mendes EN, Rocha GA, et al. Effect of Helicobacter pylori eradication on antral gastrin- and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 1993 28 : 858 64.
67. Kaneko H, Nakada K, Mitsuma T, et al. Helicobacter pylori infection induces a decrease in immunoreactive-somatostatin concentrations of human stomach. Dig Dis Sci 1992 37 : 409 16.
68. Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med 1995 27 : 569 73.
69. Graham DY, Lew GM, Lechago J. Antral G-cell and D-cell numbers in Helicobacter pylori infection: effect of H. pylori eradication. Gastroenterology 1993 104 : 1655 60.
70. Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, Ten Kate FJ. Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J Clin Pathol 2005 58 : 927 31.
71. Milutinovic AS, Todorovic V, Milosavljevic T, Micev M, Spuran M, Drndarevic N. Somatostatin and D cells in patients with gastritis in the course of Helicobacter pylori eradication: a six-month, follow-up study. Eur J Gastroenterol Hepatol 2003 15 : 755 66.
72. Park SM, Lee HR, Kim JG, et al. Effect of Helicobacter pylori infection on antral gastrin and somatostatin cells and on serum gastrin concentrations. Korean J Intern Med 1999 14 : 15 20.
73. Ohkusa T, Miwa H, Nomura T, et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients. Aliment Pharmacol Ther 2004 1 : 25 32.
74. Chen TS, Tsay SH, Chang FY, Lee SD. Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study. Am J Gastroenterol 1994 89 : 1511 4.
75. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997 113 : 15 24.
76. Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000 46 : 20 6.
77. Long SH, Berna MJ, Thill M, et al. Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results. J Clin Endocrinol Metab 2007 92 : 4394 402.
78. Isenberg JI, Walsh JH, Passaro E Jr., Moore EW, Grossman MI. Unusual effect of secretin on serum gastrin, serum calcium, and gastric acid secretion in a patient with suspected Zollinger-Ellison syndrome. Gastroenterology 1972 62 : 626 31.
79. Alexander HR, Bartlett DL, Venzon DJ, et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 1998 124 : 1160 6.
80. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006 85 : 331 64.
81. Kato M, Imamura M, Hosotani R, et al. Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg 2000 24 : 1425 30.
82. Lamers CG, Van Tongeren JH. Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome. Gut 1977 18 : 128 35.
83. Wada M, Komoto I, Doi R, Imamura M. Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 2002 26 : 1291 6.
84. Berson SA, Yalow RS. Radioimmunoassay in gastroenterology. Gastroenterology 1972 62 : 1061 84.
85. Nilsson G, Simon J, Yalow RS, Berson SA. Plasma gastrin and gastric acid responses to sham feeding and feeding in dogs. Gastroenterology 1972 63 : 51 9.
86. Langer P, Wild A, Celik I, Kopp I, Bergenfelz A, Bartsch DK. Prospective controlled trial of a standardized meal stimulation test in the detection of pancreaticoduodenal endocrine tumours in patients with multiple endocrine neoplasia type 1. Br J Surg 2001 88 : 1403 7.
87. Korman MG, Soveny C, Hansky J. Effect of glucagon on serum gastrin. II. Studies in pernicious anaemia and the Zollinger-Ellison syndrome. Gut 1973 14 : 459 61.
88. Shibata C, Funayama Y, Fukushima K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg 2008 12 : 344 9.
89. Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology 2004 1 : 23 7.
90. Delle FG, Kohn A, De ML, et al. Effects of bombesin on gastrin and gastric acid secretion in patients with duodenal ulcer. Gut 1983 24 : 231 5.
91. Aoyagi T, Summerskill WH. Gastric secretion with ulcerogenic islet cell tumor. Importance of basal acid output. Arch Intern Med 1966 117 : 667 72.
92. Kaye MD, Rhodes J, Beck P. Gastric secretion in duodenal ulcer, with particular reference to the diagnosis of Zollinger-Ellison syndrome. Gastroenterology 1970 58 : 476 81.
93. Jensen RT, Gardner JD, Raufman JP, Pandol SJ, Doppman JL, Collen MJ. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 1983 98 : 59 75.
94. Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973 65 : 140 65.
95. Metz DC, Starr JA. A retrospective study of the usefulness of acid secretory testing. Aliment Pharmacol Ther 2000 14 : 103 11.
96. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 1983 84 : 108 13.
97. Wank SA, Doppman JL, Miller DL, et al. Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987 92 905 12.
98. Maton PN, Miller DL, Doppman JL, et al. Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. Gastroenterology 1987 92 : 913 8.
99. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997 112 : 335 47.
100. Turner JJ, Wren AM, Jackson JE, Thakker RV, Meeran K. Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 2002 57 : 821 5.
101. Imamura M, Takahashi K, Adachi H, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 1987 205 : 230 9.
102. Imamura M, Takahashi K. Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World J Surg 1993 17 : 433 8.
103. Rosato FE, Bonn J, Shapiro M, BarBot DJ, Furnary AM, Gardiner GA. Selective arterial stimulation of secretin in localization of gastrinomas. Surg Gynecol Obstet 1990 171 : 196 200.
104. Dhillo WS, Jayasena CN, Jackson JE, et al. Localization of gastrinomas by selective intra-arterial calcium injection in patients on proton pump inhibitor or H2 receptor antagonist therapy. Eur J Gastroenterol Hepatol 2005 17 : 429 33.
105. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001 15 : 1555 61.
106. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008 135 : 1469 92.